Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRC PET Component
NCT07758660Phase 2Enrolling by invitation
- Start
- Aug 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
A Phase 2 trial of florquinitau, florbetaben in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), Dementia. Started Aug 2026; status: enrolling by invitation.
02
Drugs
florquinitauflorbetaben
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on NCT07758660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758660.